Confirmation of a Computer-derived Nomogram To Predict Gentamicin Serum Concentrations in Postsurgical Patients

Wl, Russell; Mcneely, D; Yost, Richard L.; Jp, O'Leary

doi:10.1093/ajhp/35.5.570

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wide interpatient variability in aminoglycoside pharmacokinetics has led to a variety of methods for individualising therapy (Abel & Aronoff 1984;Bottger et al 1988;Burton et al 1985Burton et al , 1986Chow et al 1978;Chrystyn 1988;Denaro & Ravenscroft 1989;Garraffo et al 1989;Godley et al 1988;Hatton et al 1984;Katz & Argenio 1986;Lacarelle et al 1987;Lazurko et al 1981;McClellan & Farringer 1989;Murray et al 1986;Robinson et al 1984;Rodvold & Blum 1987;Russell et al 1978;Sheiner & Stuart 1981). Recent literature has suggested that haematology/oncology patients may also show variation in aminoglycoside pharmacokinetics (Higa & Murray 1987;Manny & Hutson 1986).…”

Section: Discussionmentioning

confidence: 99%

Aminoglycoside Forecasting in Neutropenic Patients with Cancer

Kosirog

Rospond

Destache

et al. 1993

Clinical Pharmacokinetics

View full text Add to dashboard Cite

To validate the population pharmacokinetic parameters of aminoglycoside disposition in patients with cancer, a retrospective evaluation of predictive performance of a Bayesian program was performed in 155 patients from 1986 to 1989 who received amikacin, gentamicin or tobramycin. Each patient received 1 of the 3 drugs and had initial drug concentration determination, with a second set of drug concentrations drawn < or = 14 days after the initial dose. Predictions of 64 amikacin, 144 gentamicin and 102 tobramycin concentrations were generated using 1-compartment model pharmacokinetic parameters, serum creatinine values, patients' dosage history and demographic data. The mean (+/- SD) observed (and predicted) serum concentrations for amikacin were 18.9 +/- 14.8 mg/L (17.2 +/- 14.1 mg/L); for gentamicin were 4.49 +/- 3.58 mg/L (4.26 +/- 3.33 mg/L) and for tobramycin were 4.52 +/- 3.70 mg/L (4.05 +/- 3.49 mg/L) [p > 0.05]. Results demonstrated minimal bias with a mean error in gentamicin concentrations of -0.236 (95% CI -0.533: 0.0613). Significant (p < 0.05) under prediction occurred in concentrations of tobramycin [-0.474 mg/L (95% CI -0.842: -0.0107)] and amikacin [-1.77 mg/L (95% CI -3.42: -0.114)]. Good precision is indicated by a mean squared error for gentamicin of 3.35 mg/L (95% CI 1.70: 4.99) and for tobramycin of 3.64 mg/L (95% CI 1.83: 5.44). Fair precision is demonstrated by amikacin [46.1 mg/L (95% CI 27.3: 65.0)]. Similar results were shown in a separate peak/trough analysis. These data indicate that aminoglycoside pharmacokinetics in patients with cancer can be predicted with minimal bias and good precision using a Bayesian forecasting program for gentamicin and tobramycin.

show abstract